TP53 and breast cancer: Upregulation of APOBEC3s (particularly the B) in breast cancer leads to an increase in TP53 and PIK3CA mutations [18,35], which is linked to tumorigenesis, poor prognosis, and resistance to many anti-cancer drugs [36].